◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

HomeAll stocksCYTK › Free Cash Flow

Cytokinetics Inc (CYTK) Free Cash Flow 2006–TTM

DATA UPDATED 2026-09-19

Cytokinetics Inc annual free cash flow for fiscal TTM was -$580 million, a decrease of 8.4% from -$535 million in fiscal 2025. All figures are reported results from public filings — no estimates or projections.

CYTK Annual Free Cash Flow

Free Cash Flow (annual)TTM → 2026-06-302025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-312010-12-312009-12-312008-12-312007-12-312006-12-31
Free Cash Flow (FCF)($580M)($535M)($400M)($416M)($311M)($191M)($2M)($94M)($102M)($105M)$35M$4M($46M)($8M)($34M)($46M)($45M)$8M($62M)($6M)($53M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

CYTK Quarterly Free Cash Flow

Free Cash Flow (quarterly)2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-30
Free Cash Flow (FCF)($164M)($151M)($148M)($117M)($132M)($137M)($67M)($104M)($101M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Free Cash Flow at Comparable Companies

More CYTK metrics: Revenue · Gross Profit · Operating Income · Net Income · EPS · EBITDA · Shares Outstanding

All CYTK financial statements → Interactive CYTK charts →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.